Fibronostics will attend AASLD’s The Liver Meeting® 2026, taking place November 5–9, 2026, at the Colorado
Convention Center in Denver, Colorado.

Brock Smith, Dr Mona Munteanu, and David Cashio will represent Fibronostics, connecting with clinicians,
researchers, and partners to discuss advances in non-invasive liver assessment.

Two posters co-authored by Dr Mona Munteanu will feature research on identifying advanced fibrosis and
supporting treatment initiation and monitoring in MASLD/MASH.

Presenting: Sequential Testing for Advanced Fibrosis LIVERFASt™ in Sequential Combination with Vibration Controlled Transient Elastography (VCTE) Outperforms FIB-4 and VCTE for Identifying Advanced Fibrosis (≥F3) in Patients with MASLD

Presentation: Friday, November 6, 2026 | 1:00–2:00 p.m.
Session: Diagnostics and Biomarkers – MASH

Presentation: Non-Invasive Assessment in Resmetirom Therapy A Multimodal Noninvasive Approach to Initiation and Monitoring of Resmetirom Therapy in MASH – Update

Presentation: Saturday, November 7, 2026 | 1:00–2:00 p.m.
Session: MASLD/MASH – Therapeutics: New Agents and Approved/Available Agents

All presentation times are local to Denver.

18–20 September 2026 | Hilton Orlando Bonnet Creek, Orlando, Florida

Fibronostics will attend the Florida Gastroenterology Society’s 61st Annual Meeting and the 50th FGS/SGNA Joint Annual Meeting in Orlando. Maria and David Cashio look forward to connecting with gastroenterology professionals and discussing practical approaches to liver assessment.

They will also introduce LIVERFASt™, which uses advanced analytics and commonly available biomarkers to provide fibrosis staging, inflammatory activity grading, and steatosis grading from a single routine blood sample. It offers a more complete view of liver health to help inform further evaluation and clinical pathways for patients with MASLD and MASH.

Attending the meeting? Connect with Maria and David in Orlando to learn more.